SRR5903551
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 64
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NC-A5HP-01A-11R-A26W-07 | — | cohortSQ1 | 0.818 |
| 2 | TCGA-43-7657-01A-31R-2125-07 | — | cohortSQ1 | 0.804 |
| 3 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.803 |
| 4 | SRR8518210 | — | E | 0.787 |
| 5 | TCGA-33-4533-01A-01R-1201-07 | — | cohortMD1 | 0.781 |
| 6 | SRR27320682 | — | — | 0.775 |
| 7 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.774 |
| 8 | TCGA-OR-A5KO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.770 |
| 9 | 2b2c2ebc-e83c-442e-88ae-1a2569ac892f | — | — | 0.770 |
| 10 | TCGA-CV-5435-01A-01R-1686-07 | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |